Piralen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Piralen

Property Description
Active Ingredient Metoclopramide hydrochloride
Pharmacological Class Antiemetic and Prokinetic Agent
Primary Forms Tablet, Oral Solution, Solution for Injection
General Purpose Regulating upper GI motility and suppressing vomiting
Origin Synthetic compound

1. Defining Piralen: A Prokinetic Antiemetic

Piralen is a distinct pharmaceutical preparation containing the single active substance, metoclopramide hydrochloride. As a generic compound, metoclopramide is clinically recognized for its unique dual therapeutic capabilities, which is why the medicine is placed in two separate pharmacological categories: it functions as both an Antiemetic agent and a Prokinetic Agent. Metoclopramide is a synthetic compound, structurally derived from the chemical class of substituted benzamides. This dual action is the key differentiating feature, allowing Piralen to provide relief by addressing the functional causes of movement impairment alongside controlling the central trigger for sickness.

2. Active Ingredient and Available Pharmaceutical Forms

The sole active ingredient and the source of Piralen's therapeutic profile is metoclopramide hydrochloride. Metoclopramide is recognized for its ability to increase the peristalsis of the duodenum and jejunum. This observation supports the drug’s role in normalizing the speed and coordination of upper gut transit. Piralen is a single-ingredient product available for flexible patient management. This versatility is provided through several dosage forms, including the most common tablets and an oral solution for the oral route, in addition to a sterile solution for injection for delivery via the intravenous route or intramuscular route in clinical settings.

3. General Purpose and Mechanism Principles

The overarching purpose of Piralen is to offer functional relief by enhancing the movement of the upper digestive system and efficiently controlling the reflex of sickness. The action of the active substance is linked to the antagonism of dopamine receptors, a mechanism that helps effectively control nausea. This ability to interrupt the central signals that stimulate the brain's vomiting center, combined with its localized stimulation of the gut, makes Piralen a crucial option for stabilizing upper gastrointestinal function when issues like delayed stomach emptying are present.

What side effects are possible with Piralen?

Piralen: Possible side effects and safety information

The official safety profile of metoclopramide hydrochloride (Piralen's active substance) is structured around high-level safety patterns documented in government regulatory sources, particularly those affecting the nervous system.

Adverse reactions are formally classified by frequency. Drowsiness, fatigue, and restlessness (akathisia) are officially categorized as Most Common or Very Common. Less frequent, or Common effects, include depression and diarrhea. Extrapyramidal disorders (involuntary movement disturbances) and somnolence represent major system-organ-class effects.

Serious Adverse Reactions and Duration-Related Risk

Regulatory documents emphasize the risk of Tardive Dyskinesia (TD), a potentially irreversible movement disorder. The risk of TD is formally stated to increase with the duration of treatment and the total cumulative dose, leading to regulatory caution against prolonged use. Other serious adverse reactions documented in official labeling include Neuroleptic Malignant Syndrome (NMS) and severe cardiovascular events such as cardiac arrest, especially following rapid intravenous delivery.

Acute Extrapyramidal Symptoms (EPS), like involuntary muscle contractions (dystonia), typically occur at the beginning of treatment and can occur after a single exposure.

Population-Specific Safety Considerations

Safety notes address specific patient populations. Older adults may exhibit increased sensitivity to neurological adverse reactions, including sedation and movement disorders. Pediatric patients, especially neonates, have a documented increased risk of extrapyramidal symptoms and a specific blood disorder called methemoglobinemia. Patients with renal or severe hepatic impairment are also noted in official documents as requiring adjustments due to reduced drug clearance.

Official labeling contraindicates the use of Piralen in the presence of certain conditions, including gastrointestinal hemorrhage, mechanical obstruction, or perforation, as well as in individuals with pheochromocytoma or epilepsy.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Piralen


Overdose Scope

Element Official Regulatory Statement
Documented Overdose Presentations Drowsiness, Disorientation, Confusion, Lethargy, Seizures, and Extrapyramidal Reactions (EPS).
Physiological Systems Affected (As stated in label) Central Nervous System, Cardiovascular System (Circulatory Collapse, Severe Bradycardia), and Hematologic System (Methemoglobinemia).
Dose-related or Exposure-related Factors Severe cardiovascular effects, including Cardiac Arrest, reported following administration by the intravenous route.
Population-specific Overdose Notes (If applicable) Methemoglobinemia has occurred in premature and full-term neonates following overdosage. Unintentional overdose is reported in infants and children.
Emergency-response Statements (As written in official documents) Administration of Methylene Blue is specified for Methemoglobinemia; use of Anticholinergic or Antiparkinsonian drugs to control EPS.
When immediate medical help is required (Label-derived phrasing only) Seek immediate medical attention if symptoms such as extrapyramidal reactions occur.

Overdose Classifications (High-Level)

Element Official Regulatory Statement
Severity Classification (As defined in official documents) Severe outcomes include Circulatory Collapse and Neuroleptic Malignant Syndrome (NMS), defining a potentially life-threatening scenario.
Regulatory Basis (EMA / FDA / etc.) Based on official overdose sections found in regulatory Prescribing Information and Public Assessment Reports.
Overdose-Context Constraints (As defined in official documents) Dialysis is not likely to be an effective method of drug removal.

Resulting Overdose Structure

Official overdose statements:

  • Overdosage is associated with documented clinical signs including Drowsiness, Disorientation, and Extrapyramidal Reactions (EPS).
  • Life-threatening outcomes can include Cardiac Arrest, Circulatory Collapse, and the specific risk of Methemoglobinemia in neonates.
  • Regulator-mandated action requires individuals to Seek immediate medical attention upon the occurrence of severe neurological symptoms like EPS.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documentation defines the overdose profile by listing recognized neurological and CNS manifestations alongside potentially severe cardiovascular and hematologic outcomes. The regulatory framework explicitly dictates when to seek immediate medical attention for serious symptoms such as Extrapyramidal Reactions. Regulatory information also specifies supportive measures, including the use of specific reversal agents for complications, while noting that most common overdose symptoms are self-limiting.

Therapeutic Uses of Piralen

Main Uses of Piralen

Piralen is a medication primarily used to manage various gastrointestinal and neurological symptoms. Its active ingredient, metoclopramide, acts as a dopamine receptor antagonist that facilitates gastric emptying and modulates the central nervous system's response to nausea triggers.

Treatment of Nausea and Vomiting

The most common application of Piralen is the prevention and treatment of nausea and vomiting. It is effective in managing these symptoms when they are associated with several conditions, including:

  • Acute Migraines: To control nausea occurring during migraine attacks.
  • Post-operative Recovery: To manage nausea following surgical procedures.
  • Radiotherapy: To alleviate symptoms induced by radiation treatments.

Gastrointestinal Motility Disorders

Piralen is utilized to stimulate movement in the upper digestive tract. By increasing the contractions of the stomach and small intestine, it helps move food and liquids through the digestive system more efficiently. This makes it a primary option for:

  • Gastroparesis: A condition where the stomach empties too slowly, common in patients with diabetes.
  • Gastroesophageal Reflux Disease (GERD): It may be used in specific cases to assist with gastric emptying and reduce the backup of stomach acid into the esophagus.

Diagnostic and Medical Procedures

In clinical settings, Piralen is sometimes used to facilitate medical examinations. By accelerating the transit of materials through the stomach and into the small intestine, it can assist in:

  • Radiological Examinations: Improving the clarity of images by ensuring the movement of barium or other contrast agents.
  • Intubation Procedures: Helping to guide tubes into the small intestine for diagnostic purposes.

Benefits and Mechanism

The primary benefit of Piralen lies in its dual action. Centrally, it blocks dopamine receptors in the brain's chemoreceptor trigger zone, which suppresses the urge to vomit. Peripherally, it increases the sensitivity of tissues in the digestive tract to acetylcholine, which strengthens the muscles of the lower esophageal sphincter and increases the resting tone of the stomach. This combined effect provides relief from gastric stasis and the physical discomfort of nausea.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Piralen?

The official eligibility profile for Piralen (metoclopramide) is determined by governmental regulatory labeling, which defines both eligible populations and absolute contraindications.

Eligibility Status Key Conditions or Population
Contraindicated (Absolute Exclusion) Gastrointestinal hemorrhage, mechanical obstruction, perforation, pheochromocytoma, epilepsy, Parkinson’s disease, history of tardive dyskinesia, or use of levodopa/dopaminergic agonists.
Age-Related Contraindication Infants and children under 1 year of age.

Populations Requiring Restricted or Conditional Use

Restriction Type Regulatory Rule
Pediatric Use (1–18 years) Restricted to prevention of delayed CINV and treatment of PONV; use for other indications is not recommended.
Organ Function Mandatory dose reduction required for severe renal impairment or severe hepatic impairment.
Duration of Use Treatment must generally not exceed 12 weeks for chronic use, or 5 days for acute indications.
Reproductive Status Avoided at the end of pregnancy; risk-benefit assessment required during lactation.

These regulatory statements define who may and who must not use Piralen. Eligibility is based on a system of absolute non-eligibility (contraindications) and conditional use, requiring adherence to specific limitations on treatment duration for certain patient populations.

What should I know about interactions with other medicines?

The official interaction profile for Piralen, which contains metoclopramide hydrochloride, is structured around documented pharmacodynamic and pharmacokinetic patterns established by regulatory bodies.

Interaction-Related Restrictions

A formal contraindication exists for co-administration with Levodopa and other Dopaminergic Agonists due to mutual antagonism. Use with other medicines that officially increase the risk of Extrapyramidal Reactions (EPS) is also restricted.

Pharmacodynamic and Substance Interactions

Pharmacodynamically, Piralen may have an additive effect with other Central Nervous System (CNS) Depressants, including alcohol (ethanol), which can potentiate sedative effects. Anticholinergics and Morphine Derivatives have official documentation of potential antagonism of the prokinetic effect.

Exposure-Altering Interactions

Pharmacokinetic interactions are documented based on altered drug concentration. Piralen increases the bioavailability of drugs like Cyclosporine and the absorption rate of Acetaminophen and Tetracyclines. Conversely, Piralen is documented to decrease the bioavailability of Digoxin. Additionally, co-administration with Strong CYP2D6 Inhibitors can increase Piralen exposure due to reduced clearance.

Population-Specific Notes

Official regulatory considerations confirm that renal impairment, hepatic impairment, and the status of CYP2D6 Poor Metabolizers are associated with an increased risk of drug accumulation and potential heightened interaction effects.

Mechanism of Action

Piralen functions as a highly specific inhibitor of farnesyl pyrophosphate synthase (FPPS), a key enzyme within the mevalonate pathway. Following administration, the drug's active metabolite concentrates in target tissues and selectively binds to and inhibits FPPS.

This enzymatic inhibition prevents the synthesis of essential isoprenoid precursors, including farnesyl pyrophosphate and geranylgeranyl pyrophosphate. A direct downstream consequence is the reduced availability of these lipids for the post-translational modification, or prenylation, of specific regulatory proteins. Small signaling molecules, notably the small GTPases (e.g., Rho, Ras), require prenylation to correctly anchor to the cell membrane and become functionally active.

The resulting lack of prenylation prevents the membrane localization and activation of these GTPases. This molecular cascade ultimately leads to the disruption of intracellular signaling pathways that govern cytoskeletal rearrangement, cell proliferation, and overall cell survival, culminating in the targeted physiological modulation of cellular activity within specific biological systems.

Dosage and Administration Information

Piralen, a brand name for the active ingredient metoclopramide, is a prescription medication used to manage certain gastrointestinal motility disorders and prevent nausea and vomiting. Proper administration is crucial for maximizing therapeutic effect and minimizing the risk of adverse neurological reactions.

General Administration Guidelines

  • Dosage and Duration: The dose and duration of treatment must be determined by a healthcare professional based on the specific condition being treated, such as symptomatic gastroesophageal reflux or diabetic gastroparesis. Treatment with metoclopramide is generally recommended to be short-term, typically not exceeding 12 weeks, due to the risk of developing tardive dyskinesia, a serious, potentially irreversible movement disorder.
  • Timing: For oral formulations (tablets or solution), Piralen is typically taken approximately 30 minutes before each meal and at bedtime. It should be taken on an empty stomach with a glass of water.
  • Measuring Oral Liquid: If using the oral liquid, utilize an accurately calibrated measuring device, such as an oral syringe, rather than a household spoon to ensure the prescribed dose is administered correctly.

Dosage Overview (Adults)

Condition Typical Individual Dose Maximum Daily Dose
Diabetic Gastroparesis 10 mg 40 mg (for 2–8 weeks)
Gastroesophageal Reflux 10–15 mg 60 mg (for 4–12 weeks)

Note: Dosage adjustments may be necessary for patients with renal impairment (creatinine clearance le 60 mL/min), hepatic impairment, or in the elderly, as these factors can affect the drug's clearance and increase the risk of adverse effects. Do not discontinue or change the dosage without first consulting your doctor.

Recent Clinical Evidence

Research evidence / Overview of Studies for Piralen

Evidence for Use in Diabetic Gastroparesis (Delayed Stomach Emptying)

Research exploring how symptoms change over time has primarily involved short-term, placebo-controlled randomized clinical trials (RCTs). These studies were generally conducted in adult patients with diabetes who had a documented delay in their stomach emptying. Studies monitored patient-reported outcomes describing perceived discomfort, such as changes in the severity of nausea, vomiting, and feelings of upper abdominal fullness. Trials reported that patterns indicating an acceleration of the stomach emptying rate were observed in the group studied.

However, some research highlights a finding where the objective change in the rate of stomach emptying did not always align with the magnitude of change reported in outcomes related to physical discomfort by the patients themselves. Follow-up durations were limited in most key trials, often to courses not exceeding 12 weeks. There is limited information for long-term outcomes regarding the durability of symptom patterns over extended periods.

Evidence for Nausea Prevention in Postoperative and Clinical Settings

Research has explored study objectives related to preventing sickness and vomiting in situations involving heightened symptom activity.

Studies on Postoperative Nausea and Vomiting (PONV) Prevention

Multiple systematic reviews and meta-analyses of controlled trials exist. Research examined the active ingredient as a preventive measure in adults undergoing various types of surgery. Studies monitored outcomes describing episodic or acute changes, specifically the incidence of nausea and vomiting within the first 24 hours after the procedure. Findings describe patterns where the measured incidence of early and 24-hour vomiting was lower in the observed population compared to the placebo group.

Studies on Chemotherapy-Induced Nausea and Vomiting (CINV)

Research was studied for its role in managing conditions involving periods of heightened symptoms related to specific chemotherapy agents. Studies monitored outcomes related to systemic or functional imbalance in both the acute phase (the first 24 hours) and the delayed phase (the days following) of chemotherapy. Research currently shows patterns where the measured anti-sickness outcomes for acute sickness were different from those reported for certain other treatments evaluated in the studies.

Key Studies & References

  1. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis
  2. Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Health Professional Version
  3. 2019 Antiemetic Recommendations for Chemotherapy-Induced Nausea and Vomiting: A Clinical Practice Guideline - Cancer Care Ontario

Frequently Asked Questions (FAQ)

Common questions about Piralen (FAQ)

Q: What are the official guidelines for stopping Piralen?

If Piralen was taken for a long period or at high doses, sudden discontinuation may cause temporary withdrawal symptoms, such as nervousness or headaches. Official guidelines indicate that a healthcare provider may slowly lower the dose over time to help prevent these effects. Stopping or changing the dose is a process that is discussed with a healthcare provider.

Q: Does Piralen cause weight gain or weight loss?

Clinical information indicates that unintended weight gain has been reported by some patients. This medication may cause changes in certain hormone levels which could be associated with transient fluid retention. Persistent or concerning weight changes are typically reviewed with a healthcare provider.

Q: What should I do if the side effects of Piralen feel strong?

If serious symptoms occur, such as unusual, uncontrolled movements of the face or limbs, fever, or a fast heartbeat, these symptoms warrant immediate medical attention. For strong but non-emergency side effects like severe drowsiness, these effects are typically reviewed by a healthcare provider.

Q: Is Piralen safe for women who are pregnant or planning to be?

Studies suggest that Piralen may be used during pregnancy if a doctor determines that the expected benefits outweigh the potential risks. However, official product information advises caution and avoidance of use near the end of pregnancy. The status of pregnancy, pregnancy planning, or breastfeeding is information that is typically reviewed with a healthcare provider.

Q: What happens if I miss a dose of Piralen?

Official guidance indicates that a missed dose is taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped. Regulatory guidance advises against taking a double dose to compensate for a missed one.

Q: How does Piralen affect my driving ability?

Regulatory documents include warnings that Piralen can cause side effects like drowsiness, dizziness, and movement disorders. These effects can seriously impair the ability to drive or operate machinery. Official warnings advise against driving or engaging in hazardous activities until the individual knows how the medication affects them.

Q: Is Piralen suitable for people with diabetes or heart issues?

Official labeling states that Piralen should be used with caution in people with certain heart conditions, such as congestive heart failure. For patients with diabetes, the medication may affect blood sugar levels, and therefore, close monitoring by a healthcare provider is often implemented.

Q: Does Piralen have a 'black box' warning, and what does it mean?

Yes, Piralen carries a Boxed Warning—often referred to as a 'black box' warning—which is the FDA's most serious warning. This warning relates to the risk of Tardive Dyskinesia (TD), a movement disorder that can be serious and potentially permanent. The warning states that the risk increases with the duration of treatment, and official guidelines generally advise against chronic use exceeding 12 weeks.

Q: How quickly does Piralen usually start to have an effect?

Following an oral dose, the drug's effect on the body generally begins within 30 to 60 minutes. The effect typically lasts for a few hours. The overall time it takes to see an improvement in chronic symptoms can vary.

Q: Is Piralen the same as [Name of similar OTC drug]?

Piralen is the brand name for the active ingredient metoclopramide, which is strictly a prescription-only medication. It is not available over-the-counter and is only dispensed for specific medical conditions as determined by a healthcare professional.

Q: Is it common to feel a little dizzy when starting Piralen?

Official product information lists dizziness as a common side effect of this medication. This is usually due to the way the drug affects the central nervous system. Severe or persistent dizziness is a symptom that is typically reviewed by a healthcare provider.

Q: Can Piralen affect my sleep schedule?

Yes, official safety information indicates that Piralen can affect sleep. Both drowsiness and insomnia (difficulty sleeping or staying asleep) are listed as possible side effects. Persistent changes to sleep are typically reported to a healthcare provider.

Q: Are there any specific vitamins or supplements that interact with Piralen?

While specific interactions with every vitamin or supplement are not detailed, official advice strongly recommends reporting all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products to a healthcare provider or pharmacist.

Q: Is Piralen safe for use in older adults?

Regulatory warnings indicate that older adults, especially elderly women, are at an increased risk of neurological side effects like Tardive Dyskinesia (TD) and sedation. Therefore, a dose reduction is often considered in this population based on their overall health and organ function.

Q: What is the difference between Piralen and the generic version?

Piralen is the original brand name for the drug containing metoclopramide hydrochloride. The generic version contains the identical active ingredient. Both the brand and generic versions are prescription-only and are expected to work the same way in the body.

Q: Does Piralen work immediately for chronic conditions?

While the pharmacological effect starts within an hour, the drug is primarily used for short-term courses, often not exceeding 12 weeks, for chronic conditions like diabetic gastroparesis. A doctor determines if the benefits are seen within the limited treatment period.

Q: Can Piralen cause mood changes or anxiety?

Yes, official safety information lists mood changes, including anxiety, agitation, restlessness, and depression, as possible side effects. In rare cases, more severe psychiatric symptoms, including suicidal thoughts, have been reported.

Q: Is Piralen considered an addictive medicine?

The medication is not typically classified as an addictive substance. However, official information notes that physical dependence can develop, and stopping it abruptly after long-term use can lead to withdrawal symptoms.

Q: How often do the side effects of Piralen occur?

Side effects are formally classified by frequency in regulatory documents. Many common effects, such as drowsiness, tiredness, and dizziness, are reported to occur in more than 1 in 100 people. Less common effects occur at lower rates.

Q: How does Piralen get processed by the liver or kidneys?

The drug is primarily metabolized (broken down) by enzymes in the liver. Most of the drug is then eliminated through the kidneys via the urine. For patients with kidney impairment, a reduction in the maintenance dosage is necessary to prevent the drug from accumulating in the body.

Q: Are there any long-term health risks associated with Piralen use?

The primary long-term health risk noted in the Boxed Warning is Tardive Dyskinesia (TD), which can develop with prolonged use. Because of this risk, official guidelines generally recommend that the duration of treatment should not exceed 12 weeks for non-cancer conditions.

Q: Does Piralen cause dependence or withdrawal symptoms?

Official information indicates that physical dependence may occur. Abruptly stopping the medication after long-term or high-dose use can cause withdrawal symptoms like nervousness, headaches, or dizziness. A doctor will typically provide instructions for safely lowering the dose.

Q: Can Piralen be taken with blood pressure medication?

Piralen can affect blood pressure and may interact with certain blood pressure medications. The need to monitor vital signs and manage potential interactions is a standard regulatory consideration for healthcare providers.

Q: Does Piralen interact with hormonal birth control?

If Piralen causes severe diarrhea that lasts for more than 24 hours, this severe gastrointestinal upset may reduce the effectiveness of oral contraceptive pills. Official advice suggests consulting the specific instructions in the pill packet for guidance on using backup contraception in this situation.

How should Piralen be stored and disposed of?

How to Store and Dispose of Piralen (Metoclopramide)

Storage Requirements

Piralen must be stored at room temperature, typically defined as 20 C to 25 C. It is mandatory to keep the medication out of the sight and reach of children.

To preserve the product’s integrity, storage must be away from excess heat and moisture and away from direct light. The container must be kept tightly closed and the product should be stored in the container in which it was dispensed. It is required to keep the medicine from freezing.

Handling and Disposal

Single-use forms, such as the injectable solution, must have any unused portion discarded immediately. Unused or expired Piralen must not be disposed of in household trash or wastewater. Patients must consult a healthcare professional or pharmacist regarding the proper disposal of any unused medicine, adhering strictly to local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Piralen found in:

A-Z Index: